Core Insights - The company, Jitai Technology, has launched the world's first AI-driven nano delivery platform, NanoForge, which integrates quantum chemistry and molecular dynamics simulations for drug delivery optimization [1][2] - NanoForge enables a closed-loop process from molecular generation to formulation design, leveraging a large-scale library of over 10 million LNP lipid structures [1][2] - Jitai Technology has developed three major solutions based on NanoForge: AiLNP, AiRNA, and AiTEM, focusing on nucleic acid delivery, mRNA sequence design, and small molecule formulation design respectively [1][2] Company Developments - Jitai Technology has identified LNP targeted delivery for eight organs or tissues, with over 100 authorized and filed patent applications [2] - The company has successfully developed more than 10 pipeline projects, producing 7 preclinical candidates and advancing 4 clinical projects, with the fastest pipeline reaching the pre-NDA stage [2] - The CEO of Jitai Technology emphasized the shift from biotechnology to tech-driven biology, highlighting the efficiency and technological breakthroughs achieved through the integration of large model innovations and iterative experiments [2] Financial and Strategic Moves - In August, Jitai Technology completed a Series D financing round, raising a total of 400 million yuan, led by the Beijing Pharmaceutical Health Industry Investment Fund and the Daxing District Industrial Investment Fund [2] - The funds raised will accelerate the company's strategic initiatives, including platform automation upgrades, advancement of self-developed product pipelines, deepening international collaborations, and attracting high-end talent [2]